{"id":"partics-using-qvar","_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PARTICS using QVAR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:22:12.291316+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:22:27.953157+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T06:22:17.819924+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PARTICS using QVAR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:22:17.996044+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5776358/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:22:19.302497+00:00"}},"_dailymed":null,"aiSummary":"PARTICS using QVAR is a marketed drug developed by Brigham and Women's Hospital, currently holding a position in the respiratory therapy segment. The key composition patent is set to expire in 2028, providing a clear period of exclusivity and potential revenue protection. The primary risk lies in the lack of disclosed primary trial results and competitors, which may impact the drug’s long-term market sustainability and competitive edge.","_scrapedAt":"2026-03-27T23:59:54.804Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:22:27.953243+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT02995733","phase":"PHASE4","title":"Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-11-27","conditions":"Asthma","enrollment":1220}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL5776358"},"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Patient Activated Reliever-Triggered Inhaled CorticoSteroid"],"phase":"marketed","status":"active","brandName":"PARTICS using QVAR","genericName":"PARTICS using QVAR","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:22:27.953243+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}